FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended
phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab in Patients with
Advanced Solid Tumors. And in phase II to assess the anti-tumor efficacy of EVER4010001 in
combination with Pembrolizumab in treating selected indications using appropriate biomarkers.